CLINICAL TRIALS PROFILE FOR DEXILANT
✉ Email this page to a colleague
All Clinical Trials for dexilant
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00251693 ↗ | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis | Completed | Takeda | Phase 3 | 2005-12-01 | The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis. |
| NCT00251719 ↗ | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis | Completed | Takeda | Phase 3 | 2005-12-01 | This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis. |
| NCT00251745 ↗ | Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn | Completed | Takeda | Phase 3 | 2005-12-01 | The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD). |
| NCT00251758 ↗ | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn | Completed | Takeda | Phase 3 | 2005-12-01 | The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD). |
| NCT00255151 ↗ | Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis | Completed | Takeda | Phase 3 | 2006-01-01 | The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE). |
| NCT00255164 ↗ | Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis | Completed | Takeda | Phase 3 | 2006-01-01 | The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE). |
| NCT00255190 ↗ | Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn | Completed | Takeda | Phase 3 | 2006-01-01 | The purpose of this study is to determine the long-term safety profile of daily treatment with dexlansoprazole MR in subjects with gastroesophageal reflux disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dexilant
Condition Name
Clinical Trial Locations for dexilant
Trials by Country
Clinical Trial Progress for dexilant
Clinical Trial Phase
Clinical Trial Sponsors for dexilant
Sponsor Name
